

DECISION-MAKER:	Health and Wellbeing Board
SUBJECT:	Pharmaceutical Needs Assessment Final Report and Process for dealing with changes
DATE OF DECISION:	21st September 2022
REPORT OF:	COUNCILLOR FIELKER CABINET MEMBER FOR HEALTH, ADULTS AND LEISURE

<u>CONTACT DETAILS</u>			
Executive Director	Title	Director of Commissioning, Integrated Health and Care	
	Name:	Terry Clark	Tel: 023 80
	E-mail	Terry.Clark@nhs.net	
Author:	Title	Public Health Consultant	
	Name:	Becky Wilkinson	Tel: 07774 336072
	E-mail	Becky.Wilkinson@southampton.gov.uk	

STATEMENT OF CONFIDENTIALITY	
NOT APPLICABLE	
BRIEF SUMMARY	
<p>The Health and Wellbeing Board (HWB) has a statutory responsibility to publish a statement of the needs for pharmaceutical services of the population in its area, referred to as a Pharmaceutical Needs Assessment (PNA).</p> <p>The draft PNA was approved by the HWB in March 2022 and was then subject to a 60-day statutory consultation. The main finding of the PNA draft report was that, in Southampton, the number, distribution and choice of pharmaceutical services meet the current and future needs of the population. Therefore, there was no identified need for improvements or better access to pharmaceutical services in the city. This finding was endorsed by the majority of the consultation responses.</p> <p>This briefing reports on the consultation responses to the draft PNA and proposes that no change is made to the PNA report as a result.</p> <p>This briefing also describes the on-going responsibilities of the HWB in respect to changes to the need for, or the availability of, pharmaceutical services during the lifetime of the PNA and proposes a process for dealing with these changes.</p> <p>The HWB is asked to approve both the PNA final report and the process for dealing with changes.</p>	
RECOMMENDATIONS:	
(i)	To approve the PNA final report

	(ii)	To approve the process for dealing with changes to the need for, or the availability of, pharmaceutical services during the lifetime of the PNA
--	------	---

REASONS FOR REPORT RECOMMENDATIONS

1.	<p>The PNA report has been prepared using national guidelines, following a process agreed by the HWB and with guidance from the PNA Steering Group. The consultation on the draft PNA also followed due process and the responses were analysed by the SCC Research and Insights team then given thorough consideration by the PNA Steering Group.</p> <p>The proposed process for dealing with changes during the lifetime of the PNA is based on national guidance and has been developed through discussion with the PNA Steering Group.</p>
----	---

ALTERNATIVE OPTIONS CONSIDERED AND REJECTED

	NOT APPLICABLE
--	----------------

DETAIL (Including consultation carried out)

	<p><u>Final PNA Report following the Consultation</u></p> <p>A consultation on the draft PNA Report was held, in line with the statutory requirements, during April and May 2022.</p> <p>The PNA steering group considered the consultation responses and, as the majority of respondents supported the conclusions of the PNA, the group agreed that no changes to the document should be made.</p> <p>Appendix 1 of this briefing is a report of the consultation which will also be made available on the PNA pages of the SCC Data Observatory website; a summary of this report, and of the steering group’s considerations, is included as Appendix C in Part 2 of the PNA Report (see Appendix 3 of this briefing).</p> <p>The two parts of the final PNA report, following the consultation, are included as Appendix 2 and 3. Note the only changes from the draft PNA report (which was approved by the HWB in March 2022) are to report on the consultation and the fact that no change to the PNA conclusions is required as a result.</p> <p><u>Process for dealing with changes to pharmaceutical services</u></p> <p>Appendix 4 sets out a process for dealing with changes to the need for, or the availability of, pharmaceutical services during the lifetime of the PNA. This sets out the legal responsibilities for HWBs in relation to the requirements for producing a new PNA or publishing a ‘supplementary statement’ (which is statement of fact describing significant changes to the availability of pharmaceutical services).</p> <p>The main stages of the process are as follows:</p> <p>Any significant changes in the need for pharmaceutical services will be identified via a standing item at the Southampton Joint Strategic Needs Assessment (JSNA) Steering Group. The changes will then be reported to the</p>
--	---

	<p>named Public Health Consultant leading on the PNA who will be responsible for briefing the HWB, or delegated sub-committee, of the change. The HWB (or sub-committee) will decide whether producing a new PNA would be a disproportionate response to the changes identified.</p> <p>NHS England (NHSE) provide quarterly updates on changes in the availability of pharmaceutical services to interested parties. Going forward, NHSE have been asked to include the generic email address strategic.analysis@southampton.gov.uk in the distribution list for these updates. This email address is checked at least once a week by the Data, Intelligence and Insight Team.</p> <p>The Data, Intelligence and Insight Team will make the first check of the notified change to see if any further action is required. This will include updating a map, if necessary, which will be held on the PNA pages of the Data Observatory website to show the locations of pharmaceutical services in the city.</p> <p>If further action is required, or if there is any uncertainty, the change will be escalated to the named Public Health Consultant leading on the PNA who will be responsible for briefing the HWB of the change.</p> <p>The HWB, or delegated sub-committee, will use the decision-making flowchart from national guidance to decide if a new PNA or supplementary statement is needed.</p> <p>If a supplementary statement is needed, the HWB will use the templates available in the national guidance and publish the statement on the PNA pages of the SCC Data Observatory website.</p>
--	--

RESOURCE IMPLICATIONS

Capital/Revenue

None

Property/Other

None

LEGAL IMPLICATIONS

Statutory power to undertake proposals in the report:

There is a legal duty to undertake this work as part of the NHS (Pharmaceutical & LPS) Regulations 2013, which result from the amended Health Act 2009.

Other Legal Implications:

None

RISK MANAGEMENT IMPLICATIONS

If the final PNA report is not adopted by the HWB at its September meeting, then there is a risk of not meeting the deadline for publication of 1st October

	2022 (in a form that complies with the minimum requirements set out in the 2013 regulations) which presents a theoretical risk of judicial review.
POLICY FRAMEWORK IMPLICATIONS	
	None

KEY DECISION?	N/A
WARDS/COMMUNITIES AFFECTED:	All
<u>SUPPORTING DOCUMENTATION</u>	
Appendices	
1.	Report of the PNA consultation
2.	PNA Report Part 1 Main: Report
3.	PNA Report Part 2: Appendices
4.	Process for dealing with changes in the need for, or the availability of, pharmaceutical services

Documents In Members' Rooms

	None
--	------

Equality Impact Assessment

Do the implications/subject of the report require an Equality and Safety Impact Assessment (ESIA) to be carried out.	Yes (included in Part 2 of the Final PNA report – see Appendix 3)
---	--

Data Protection Impact Assessment

Do the implications/subject of the report require a Data Protection Impact Assessment (DPIA) to be carried out.	No
--	-----------

Other Background Documents

Other Background documents available for inspection at:

Title of Background Paper(s)	Relevant Paragraph of the Access to Information Procedure Rules / Schedule 12A allowing document to be Exempt/Confidential (if applicable)
	None